Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Non-small Cell Lung Cancer

University of CreteSmall moleculePhase 4 / ApprovedActive
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
59/ 100

Competitive context

216 Active assets in the Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Endostar
Henan Cancer Hospital
Phase 4BB
Gefetinib
Brigham and Women's Hospital
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 4BB
LENVATINIB
Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →